Tests an SGLT2 inhibitor in heart attack patients at high risk of heart failure
Tests an SGLT2 inhibitor given around coronary intervention in adults with heart attack.
Key facts
- Who runs it
- Samsung Medical Center
- Where
- Seoul, South KoreaSee the site
- Trial code
- Registry title
- Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- 5 Jul 2021
- Planned end
- 30 Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- SGLT2 inhibitor
- Control
- Record updated
- 26 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a heart attack who are at high risk of heart failure and are having a stent procedure (PCI). It tests an SGLT-2 inhibitor against a control group.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Type 1 heart attack (ST-segment elevation or non-ST-segment elevation) with a rise or fall of troponin and symptoms or ECG changes of reduced blood flow to the heart. High risk of heart failure: left ventricular ejection fraction < 50%, or signs of fluid in the lungs that need treatment.
- Earlier treatment
- People already taking an SGLT-2 inhibitor cannot join. People who had rescue PCI after a clot-dissolving drug, or facilitated PCI, cannot join.
- Biomarker or test result
- Troponin rise and/or fall with at least 1 value above the 99th percentile upper reference limit.
Main reasons for not taking part
- Previous heart attack
- Previous heart failure
- Cardiac arrest needing resuscitation before randomization
- Kidney function (glomerular filtration rate) < 30ml/min/1.73m2, or on dialysis
- Type 1 diabetes, pregnancy or breastfeeding
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- 1) Subject must be at least 18 years of age 2) Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving SGLT-2 inhibitor and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure 3) Diagnosis of Type 1 myocardial infarction (MI) (ST-segment elevation MI [STEMI] or Non-ST-segment elevation MI [NSTEMI]) i) Detection of a rise and/or fall of cardiac troponin values with at least 1 value above the 99th percentile upper reference limit ii) Symptoms or electrocardiographic changes suggesting myocardial ischemia 4) High risk of heart failure (at least one of the two criteria below are met) i) Left ventricular ejection fraction < 50% ii) Symptoms or signs of pulmonary congestion requiring treatment
Who cannot take part
- 1) Target lesion is not suitable for PCI by operator's decision 2) Patients requiring cardiopulmonary resuscitation due to cardiac arrest before randomization 3) Rescue PCI after thrombolysis or facilitated PCI 4) Previous MI 5) Previous history of heart failure 6) Patients who have been taking SGLT-2 inhibitor 7) Patients with glomerular filtration rate < 30ml/min/1.73m2 or on dialysis 8) Type 1 diabetes mellitus (DM) 9) Known hypersensitivity or contraindications to study medications (SGLT-2 inhibitor) 10) Pregnant or lactating women 11) Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
Where in South Korea
- Samsung Medical CenterSeoul, South KoreaContact: Ki Hong Choi, MDTaking people
About the trial
What the trial wants to find out
We aimed to identify whether SGLT-2 inhibitor administration before and after coronary intervention is effective in reducing the size of infarction and myocardial remodeling in patients with acute myocardial infarction (AMI) and high risk of heart failure, and its mechanism. For this reason, we compared cardiac magnetic resonance imaging (CMR) parameters and clinical outcomes between the SGLT-2 inhibitor group and the control group to confirm the efficacy and safety of SGLT-2 inhibitors.
The 2 groups in the trial
- SGLT-2 inhibitorTreatment being tested
The SGLT-2 inhibitor group will receive SGLT-2 inhibitor once daily until the end of the study period.
Treatment: SGLT2 inhibitor
- ControlPlacebo, for comparison
The control group will not receive any additional drugs.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Peri-tREatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index Measured by Cardiac maGnetic rEsonance Imaging in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention
- Plain-language title
- Tests an SGLT2 inhibitor in heart attack patients at high risk of heart failureGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Publications
- SGLT2 Inhibitor on Infarct Size and LV Remodeling by CMR in Patients With AMI.JACC. Cardiovascular interventions, 2026
- Record updated
- 26 June 2025